Frontline Dual Checkpoint Inhibition in Metastatic Melanoma Over Anti–PD-1 Monotherapy: The Case for a Comparative Randomized Controlled Trial

21 aprile 2022 Senza categoria
Frontline Dual Checkpoint Inhibition in Metastatic Melanoma Over Anti–PD-1 Monotherapy: The Case for a Comparative Randomized Controlled Trial
0 out of 5 based on 0 user ratings

Journal of Clinical Oncology, Ahead of Print.

Related Posts

Lascia un commento